Crinone (progesterone) NDC 0023-6151

NDC codes

FDA NDC Directory

Product NDC (as listed)0023-6151Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00023-6151Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0023-6151-08	00023615108	15 APPLICATOR in 1 CARTON (0023-6151-08) / 1.125 g in 1 APPLICATORMarketed from May 13, 1997

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Crinone
Generic name (nonproprietary): progesterone
Active ingredients: Progesterone — 90 mg/1.125g
Dosage form: Gel
Route: Vaginal
Labeler: Allergan, Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 020701
Marketing start: May 13, 1997
Listing expires: Dec 31, 2027
Other FDA classes: Progesterone (Chemical structure)
Identifiers: Product ID 0023-6151_ab1523af-0bbb-4231-a12c-ac52e3ec91cdSPL ID ab1523af-0bbb-4231-a12c-ac52e3ec91cdSPL set ID 75e97aa1-daa4-45f9-b2e2-1a371302914eRxCUI 153579, 153580, 312643, 312645UNII 4G7DS2Q64Y
Pharmacologic class: Progesterone

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N400023615108 followed by a unit qualifier and the quantity

Package 00023-6151-08. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 21, 2024.

Indications (excerpt from the label)

INDICATIONS AND USAGE Assisted Reproductive Technology Crinone 8% is indicated for progesterone supplementation or replacement as part of an Assisted Reproductive Technology ("ART") treatment for infertile women with progesterone deficiency. Secondary Amenorrhea Crinone 4% is indicated for the treatment of secondary amenorrhea. Crinone 8% is indicated for use in women who have failed to respond to treatment with Crinone 4%.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 020701

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 020701
Product	Strength	Form · route	Labeler	Product NDC
Crinoneprogesterone	Progesterone 45 mg/1.125g	GelVaginal	Allergan, Inc.	0023-6150